PROMEDIUS, an AI company specializing in aging and metabolic diseases, successfully showcased its chest X-ray–based osteoporosis screening software Osteo Signal at KIMES Busan 2025, held from September 26 to 28 at BEXCO, Busan.

At this year’s exhibition, PROMEDIUS participated in the KIMES INSPIRE Pavilion, a special zone dedicated to innovative companies in the fields of medical startups, SaMD (Software as a Medical Device), and digital healthcare.

In collaboration with the Korean National Tuberculosis Association, PROMEDIUS also hosted a hands-on demonstration event for visitors aged 50 and above. A total of 165 participants joined the demonstration, with approximately 32% found to be at high risk of osteoporosis according to the AI analysis.

Participants were informed in advance that the demonstration was not intended for diagnostic or therapeutic purposes. Each underwent a chest X-ray examination in a mobile screening vehicle and received an AI-generated osteoporosis risk report.

Osteo Signal analyzes the most widely performed imaging test in clinical practice—chest X-rays—to identify osteoporosis risk in individuals aged 50 and older. The software then provides results in a report format, assisting healthcare professionals in their clinical decision-making.

KIMES Busan 2025 served as a meaningful opportunity for both healthcare providers and the general public to directly experience the value of AI-powered osteoporosis screening technology.

PROMEDIUS will continue its collaboration with the Korean National Tuberculosis Association to advance early detection of osteoporosis and promote healthier aging for more people.